MedTrace Logo

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

NCT02005120 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-20

No results posted yet for this study

Summary

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. The other widely used treatment for MPE is recombinant human endostatin.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Bevacizumab

Intrapleural administration of bevacizumab

DRUG

recombinant human endostatin

Intrapleural administration of recombinant human endostatin

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Qiong Zhao, PhD · The First Affiliated Hospital, Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005120 on ClinicalTrials.gov